BOLT
Bolt Biotherapeutics, Inc.NASDAQHealthcare$4.29+14.92%ClosedMarket Cap: $8.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.35
P/S
1.23
EV/EBITDA
-0.63
DCF Value
$-116.14
FCF Yield
-421.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.6%
Operating Margin
-450.1%
Net Margin
-433.7%
ROE
-92.5%
ROA
-58.8%
ROIC
-67.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $2.5M | 52.0% | $-5.6M | $-6.6M | $-3.84 | — |
| FY 2025 | $7.7M | 80.6% | $-34.6M | $-33.4M | $-17.85 | — |
| Q3 2025 | $2.2M | 86.6% | $-7.7M | $-7.1M | $-3.72 | — |
| Q2 2025 | $1.8M | 100.0% | $-9.2M | $-8.6M | $-4.46 | — |
| Q1 2025 | $1.2M | 100.0% | $-12.1M | $-11.0M | $-0.29 | — |
| Q4 2024 | $0.00 | -Infinity% | $-15.7M | $-15.9M | $-0.42 | — |
| FY 2024 | $7.7M | 100.0% | $-73.0M | $-63.1M | $-1.65 | — |
| Q3 2024 | $1.1M | 100.0% | $-16.4M | $-15.2M | $-0.40 | — |
| Q2 2024 | $1.3M | 100.0% | $-22.6M | $-21.2M | $-0.56 | — |
| Q1 2024 | $5.3M | 91.3% | $-17.1M | $-10.8M | $-0.28 | — |
| Q4 2023 | $2.1M | -681.3% | $-19.8M | $-17.9M | $-0.47 | — |
| FY 2023 | $7.9M | -681.4% | $-76.2M | $-69.2M | $-1.83 | — |